Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Repeated Subcutaneous BIM 23A760 in Acromegalic Patients
2009-010787-42Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Jul 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of onzigolide in acromegaly (2 arms), sponsored by Ipsen. Primary endpoint: Efficacy Endpoints. Started Jul 2009; status: terminated.
02
Drugs
onzigolide
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2009-010787-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010787-42.